Evidence map›Paper›PMID 30824544›Full record

ArticleThe Journal of biological chemistry2019

Detection of TAR DNA-binding protein 43 (TDP-43) oligomers as initial intermediate species during aggregate formation.

Rachel L French, Zachary R Grese, Himani Aligireddy, Dhruva D Dhavale, Ashley N Reeb, Niraja Kedia, Paul T Kotzbauer, Jan Bieschke, Yuna M Ayala

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed.

  1. TDP-43 Aggregation: The Healthy-Toxic Balance of the Prion-Like Domain.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Astrocytic KFrontiers in aging neuroscience · 2026
    Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Seeding competent TDP-43 persists in human patient and mouse muscle.bioRxiv : the preprint server for biology · 2024
    Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rachel L FrenchFrom the Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University, St. Louis, Missouri 63103.
Zachary R GreseFrom the Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University, St. Louis, Missouri 63103.
Himani AligireddyFrom the Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University, St. Louis, Missouri 63103.
Dhruva D Dhavalethe Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, and.ORCID 0000-0002-0096-1085
Ashley N ReebFrom the Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University, St. Louis, Missouri 63103.
Niraja Kediathe MRC Prion Unit, University College London, London W1W 7FF, United Kingdom.
Paul T Kotzbauerthe Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, and.
Jan Bieschkethe MRC Prion Unit, University College London, London W1W 7FF, United Kingdom.
Yuna M AyalaFrom the Edward A. Doisy Department of Biochemistry and Molecular Biology, Saint Louis University, St. Louis, Missouri 63103, yuna.ayala@health.slu.edu.

Funding

Neuropathology CoreP30AG013854 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MESULAM, MAREK-MARSEL M · 1996 to 2020
$28.9M
Protein Aggregation and Neurotransmitter Deficits in Parkinson DiseaseR01NS097799 · NINDS · WASHINGTON UNIVERSITY · PI PAUL T KOTZBAUER · 2016 to 2026
$5.8M
The Role of TDP-43 Phosphorylation in Protein Function and NeurodegenerationK01NS082391 · NINDS · SAINT LOUIS UNIVERSITY · PI AYALA, YUNA · 2013 to 2015
$617k
Medical Research Council MC_UU_00024/6Medical Research Council MR/M02492X/1NIA NIH HHS P30 AG013854NINDS NIH HHS K01 NS082391NINDS NIH HHS R01 NS097799
6 · The paper itself

Abstract

Aggregates of the RNA-binding protein TDP-43 (TAR DNA-binding protein) are a hallmark of the overlapping neurodegenerative disorders amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. The process of TDP-43 aggregation remains poorly understood, and whether it includes formation of intermediate complexes is unknown. Here, we analyzed aggregates derived from purified TDP-43 under semidenaturing conditions, identifying distinct oligomeric complexes at the initial time points before the formation of large aggregates. We found that this early oligomerization stage is primarily driven by TDP-43's RNA-binding region. Specific binding to GU-rich RNA strongly inhibited both TDP-43 oligomerization and aggregation, suggesting that RNA interactions are critical for maintaining TDP-43 solubility. Moreover, we analyzed TDP-43 liquid-liquid phase separation and detected similar detergent-resistant oligomers upon maturation of liquid droplets into solid-like fibrils. These results strongly suggest that the oligomers form during the early steps of TDP-43 misfolding. Importantly, the ALS-linked TDP-43 mutations A315T and M337V significantly accelerate aggregation, rapidly decreasing the monomeric population and shortening the oligomeric phase. We also show that aggregates generated from purified TDP-43 seed intracellular aggregation detected by established TDP-43 pathology markers. Remarkably, cytoplasmic aggregate seeding was detected earlier for the A315T and M337V variants and was 50% more widespread than for WT TDP-43 aggregates. We provide evidence for an initial step of TDP-43 self-assembly into intermediate oligomeric complexes, whereby these complexes may provide a scaffold for aggregation. This process is altered by ALS-linked mutations, underscoring the role of perturbations in TDP-43 homeostasis in protein aggregation and ALS-FTD pathogenesis.

Indexed as

Amyotrophic Lateral SclerosisBiomarkersBiopolymersDisulfidesDNA-Binding ProteinsHEK293 CellsHumansMolecular WeightMutationPhase TransitionProtein FoldingRecombinant ProteinsRNA-Binding ProteinsBiomarkersBiopolymersDisulfidesDNA-Binding ProteinsRecombinant ProteinsRNA-Binding ProteinsTARDBP protein, humanALS mutationamyotrophic lateral sclerosis (ALS) (Lou Gehrig disease)frontotemporal dementia (FTD)liquid dropletliquid–liquid phase separationneurodegenerationprotein aggregationribonuclear protein (RNP)RNA binding proteinTAR DNA-binding protein 43 (TDP-43) (TARDBP)

Identifiers

PMID30824544
PMCPMC6497947

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.